ALVO
Price
$8.33
Change
+$0.29 (+3.61%)
Updated
Sep 5 closing price
Capitalization
2.6B
67 days until earnings call
CRON
Price
$2.50
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
958.33M
60 days until earnings call
Interact to see
Advertisement

ALVO vs CRON

Header iconALVO vs CRON Comparison
Open Charts ALVO vs CRONBanner chart's image
Alvotech
Price$8.33
Change+$0.29 (+3.61%)
Volume$448.25K
Capitalization2.6B
Cronos Group
Price$2.50
Change-$0.00 (-0.00%)
Volume$1.97M
Capitalization958.33M
ALVO vs CRON Comparison Chart in %
Loading...
ALVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALVO vs. CRON commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALVO is a Hold and CRON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ALVO: $8.33 vs. CRON: $2.50)
Brand notoriety: ALVO and CRON are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALVO: 112% vs. CRON: 71%
Market capitalization -- ALVO: $2.6B vs. CRON: $958.33M
ALVO [@Pharmaceuticals: Generic] is valued at $2.6B. CRON’s [@Pharmaceuticals: Generic] market capitalization is $958.33M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALVO’s FA Score shows that 1 FA rating(s) are green whileCRON’s FA Score has 1 green FA rating(s).

  • ALVO’s FA Score: 1 green, 4 red.
  • CRON’s FA Score: 1 green, 4 red.
According to our system of comparison, CRON is a better buy in the long-term than ALVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALVO’s TA Score shows that 3 TA indicator(s) are bullish while CRON’s TA Score has 1 bullish TA indicator(s).

  • ALVO’s TA Score: 3 bullish, 2 bearish.
  • CRON’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, ALVO is a better buy in the short-term than CRON.

Price Growth

ALVO (@Pharmaceuticals: Generic) experienced а +3.22% price change this week, while CRON (@Pharmaceuticals: Generic) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

ALVO is expected to report earnings on Nov 12, 2025.

CRON is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALVO($2.6B) has a higher market cap than CRON($958M). CRON has higher P/E ratio than ALVO: CRON (50.00) vs ALVO (36.22). CRON YTD gains are higher at: 23.762 vs. ALVO (-37.037). ALVO has higher annual earnings (EBITDA): 207M vs. CRON (-25.58M). CRON has more cash in the bank: 834M vs. ALVO (151M). CRON has less debt than ALVO: CRON (2.01M) vs ALVO (1.27B). ALVO has higher revenues than CRON: ALVO (560M) vs CRON (130M).
ALVOCRONALVO / CRON
Capitalization2.6B958M271%
EBITDA207M-25.58M-809%
Gain YTD-37.03723.762-156%
P/E Ratio36.2250.0072%
Revenue560M130M431%
Total Cash151M834M18%
Total Debt1.27B2.01M63,053%
FUNDAMENTALS RATINGS
CRON: Fundamental Ratings
CRON
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALVOCRON
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
45%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 11 days ago
68%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAFOX9.13N/A
N/A
BlackRock Large Cap Focus Growth Instl
NQVCX55.90N/A
N/A
Nuveen Multi Cap Value C
VSMIX27.72N/A
N/A
Invesco Small Cap Value Y
ICTVX10.19N/A
N/A
ICON Utilities and Income Inv
GGRUX15.14N/A
N/A
Goldman Sachs Strategic Growth R6

ALVO and

Correlation & Price change

A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALVO
1D Price
Change %
ALVO100%
+3.61%
EBS - ALVO
27%
Poorly correlated
-0.66%
CRON - ALVO
23%
Poorly correlated
N/A
ACB - ALVO
22%
Poorly correlated
+1.66%
PAHC - ALVO
22%
Poorly correlated
+0.97%
PBH - ALVO
21%
Poorly correlated
-2.55%
More